A multicenter phase l/ll study of obatoclax mesylate administered as a 3- Or 24-hour infusion in older patients with previously untreated acute myeloid leukemia

Academic Article


  • Purpose: An open-label phase l/ll study of single-agent obatoclax determined a maximum tolerated dose (MTD) and schedule, safety, and efficacy in older patients (≥70 yr) with untreated acute myeloid leukemia (AML).
  • Authors

    Published In

  • PLoS One  Journal
  • Digital Object Identifier (doi)

    Author List

  • Schimmer AD; Raza A; Carter TH; Claxton D; Erba H; DeAngelo DJ; Tallman MS; Goard C; Borthakur G
  • Volume

  • 9
  • Issue

  • 10